These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16440300)

  • 1. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
    Wang G; Sadar MD
    J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
    Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
    Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the androgen receptor in the development and progression of prostate cancer.
    Jenster G
    Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
    Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.
    Kim J; Jia L; Stallcup MR; Coetzee GA
    J Mol Endocrinol; 2005 Feb; 34(1):107-18. PubMed ID: 15691881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor decoy molecules block the growth of prostate cancer.
    Quayle SN; Mawji NR; Wang J; Sadar MD
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1331-6. PubMed ID: 17227854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
    Taplin ME; Balk SP
    J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
    Burnstein KL
    J Cell Biochem; 2005 Jul; 95(4):657-69. PubMed ID: 15861399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
    Bergerat JP; Céraline J
    Hum Mutat; 2009 Feb; 30(2):145-57. PubMed ID: 18800375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.
    Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J
    J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
    Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
    J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.